Drug Trial Radar · NCT07810010
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8,000
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Jul 3, 2028
Study completion Jul 5, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy, safety, and immunogenicity of a single IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate. The study will include a Safety Lead-in Cohort that will be enrolled first and will comprise 200 participants aged 60 years and older randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo (100 participants per arm). The enrollment of the Main Cohort will start after the completion of the ESDR (Early Safety Data Review), pending a positive outcome. For the Main Cohort, 7800 participants (3900 participants per arm) will be randomized in a 1:1 ratio to receive either RSV+HMPV protein vaccine or placebo.
Conditions
- Respiratory Syncytial Virus
- Human Metapneumovirus
- Healthy Volunteers
Interventions
Bivalent RSV+HMPV protein vaccineBiological
IM injection
PlaceboBiological
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of the first episode of RSV-LRTD (Lower Respiratory Tract Disease)Time frame: From 14 days to 12 months after vaccination
- Occurrence of the first episode of HMPV-LRTDTime frame: From 14 days to 12 months after vaccination
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0360008
Bruse, Australian Capital Territory, Australia · Recruiting
Investigational Site Number : 0360006
Blacktown, New South Wales, Australia · Recruiting
Investigational Site Number : 0360007
Maroubra, New South Wales, Australia · Recruiting
Investigational Site Number : 0360002
Albion, Queensland, Australia · Recruiting
Investigational Site Number : 0360003
Sippy Downs, Queensland, Australia · Recruiting
Investigational Site Number : 0360009
Melbourne, Victoria, Australia · Recruiting
Investigational Site Number : 8260003
Bradford, United Kingdom · Recruiting
Investigational Site Number : 8260004
London, United Kingdom · Recruiting
Investigational Site Number : 8260008
Stockton-on-Tees, United Kingdom · Recruiting
Investigational Site Number : 8260012
Cardiff, Cardiff [Caerdydd Gb-crd], United Kingdom · Recruiting
Investigational Site Number : 8261010
Bournemouth, Dorset, United Kingdom · Recruiting
Investigational Site Number : 8263010
Dorchester, Dorset, United Kingdom · Recruiting
Investigational Site Number : 8260013
London, England, United Kingdom · Recruiting
Investigational Site Number : 8260011
London, England, United Kingdom · Recruiting
Investigational Site Number : 8262010
Portsmouth, Hampshire, United Kingdom · Recruiting
Investigational Site Number : 8260002
Blackpool, Lancashire, United Kingdom · Recruiting
Investigational Site Number : 8260007
London, London, City of, United Kingdom · Recruiting
Investigational Site Number : 8260001
Corby, Northamptonshire, United Kingdom · Recruiting
Investigational Site Number : 8260005
Witney, Oxfordshire, United Kingdom · Recruiting
Investigational Site Number : 8260009
Bromborough, Wirral, United Kingdom · Recruiting
Investigational Site Number : 8260006
West Kirby, Wirral, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.